Finnish Breast Cancer Group (FBCG)

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Finnish Breast Cancer Group (FBCG). Clinical trials include: Comparison of vinorelbine versus docetaxel, and trastuzumab versus no trastuzumab as adjuvant treatments of early breast cancer. FinHer studyRandomized phase III study comparing single-agent docetaxel followed by 5-FU, epirubicin and cyclophosphamide (FEC) to docetaxel plus Xeloda followed by cyclophosphamide, epirubicin and Xeloda (CEX) as adjuvant treatment for early breast cancer. FinXX StudyA multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer. BREX 01-2004 Study

Download Full-text

Fondazione Michelangelo Breast Cancer Group (FM-B)

Breast Cancer Online ◽

10.1017/s1470903106009114 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 104-109

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Systemic Therapy ◽

Operable Breast Cancer ◽

List Type ◽

Cooperative Study ◽

Primary Systemic Therapy ◽

Cancer Group ◽

Current Contact ◽

Breast Cancer Group

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Fondazione Michelangelo Breast Cancer Group (FM-B). Clinical trials include: European cooperative study of chemotherapy and surgery comparing adjuvant doxorubicin followed by CMF versus adjuvant doxorubicin/paclitaxel followed by CMF versus primary doxorubicin/paclitaxel followed by CMF in women with operable breast cancer and T > 2cm.European Cooperative Study of Primary Systemic Therapy in Women with Operable Breast Cancer and T > 2cm.

Download Full-text

Breast European Adjuvant Studies Team (BREAST)

Breast Cancer Online ◽

10.1017/s1470903106009072 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 80-90

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Phase Iii ◽

List Type ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Phase Iii Trial ◽

Adjuvant Trial ◽

Current Contact ◽

Positive Breast Cancer

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Breast European Adjuvant Studies Team (BREAST). Clinical trials include: An intergroup phase III trial to evaluate the activity of docetaxel, given either sequentially or in combination with doxorubicin, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophos-phamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients. BIG 02-98/TAX 315HERA: A randomized three-arm multi-centre comparison of 1 year and 2 years of Herceptin versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy. BIG 01-01/B016348Adjuvant trial with lapatinib and trastuzumab* (BIG) *trial title/acronym not available at time of publication.

Download Full-text

West Midlands Breast Group (WMBG)

Breast Cancer Online ◽

10.1017/s1470903106009370 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 464-477

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Early Breast Cancer ◽

Early Stage ◽

Phase Iii ◽

Tamoxifen Treatment ◽

List Type ◽

West Midlands ◽

Er Positive ◽

Breast Group

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by West Midlands Breast Group (WMBG). Clinical trials include: aTTom – adjuvant Tamoxifen Treatment – offer more?Sequencing of chemotherapy and radiotherapy in adjuvant breast cancer. SECRABA phase III randomized trial of gemcitabine in paclitaxel-containing, epirubicin-based, adjuvant chemotherapy for women with early stage breast cancer. tAnGoTamoxifen and Exemestane Adjuvant Multicentre trial TEAMNeoadjuvant trial of preoperative exemestane or letrozole ± celecoxib in the treatment of ER positive postmenopausal early breast cancer NEO-EXCELA neoadjuvant study of sequential epirubicin + cyclophosphamide and paclitaxel ± gemcitabine in the treatment of high risk early breast cancer with molecular profiling, proteomics and candidate gene analysis. Neo-tAnGo

Download Full-text

American College of Surgeons Oncology Group (ACOSOG)

Breast Cancer Online ◽

10.1017/s1470903106009035 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 45-53

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Sentinel Node ◽

Axillary Node ◽

Phase Iii ◽

List Type ◽

Oncology Group ◽

Current Contact ◽

American College Of Surgeons ◽

Estrogen Receptor Positive

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by American College of Surgeons Oncology Group (ACOSOG). Clinical trials include: ACOSOG Z1031: A randomized phase III trial comparing 16–18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stages II and III estrogen receptor positive breast cancer.ACOSOG Z0010: A prognostic study of sentinel node and bone marrow micrometastases in women with clinical T1 or T2 N0 M0 breast cancer.ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node.

Download Full-text

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

European Journal of Cancer ◽

10.1016/j.ejca.2021.07.033 ◽

2021 ◽

Vol 156 ◽

pp. 138-148

Author(s):

Volker Möbus ◽

Hans-Joachim Lück ◽

Ekkehart Ladda ◽

Peter Klare ◽

Marcus Schmidt ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Randomised Trial ◽

Phase Iii ◽

Dose Dense

Download Full-text

Dutch Breast Cancer Trialists' Group (BOOG)

Breast Cancer Online ◽

10.1017/s1470903106009060 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 61-79

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

List Type ◽

First Line ◽

Open Label ◽

Phase Iii Study

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Dutch breast cancer trialists' group (BOOG). Clinical trials include:An open label randomized (inter)national multicenter comparative trial of 5 years adjuvant endocrine therapy with an LHRH agonist plus an aromatase inhibitor (goserelin + anastrozole) versus five courses FE90C chemotherapy followed by the same endocrine therapy in pre- or perimenopausal patients with hormone receptor-positive primary breast cancer (PRemenopausal Optimal Management IS Endocrine therapy). BOOG 2002-01/PROMISE. ISRCTN23561723Open label, comparative, randomized, multicenter, study of trastuzumab (Herceptin) given with docetaxel (Taxotere) versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for metastatic breast cancer (MBC) patients with HER2neu overexpression. BOOG 2002-02/HERTAX ISRCTN13770586Micro-metastases and Isolated tumour cells: Robust and Relevant Or Rubbish? The MIRROR study in BREAST CANCER. BOOG 2003-03/ZonMW 3214Radiation dose intensity study in breast cancer in young women: a randomized phase III trial of additional dose to the tumor bed. BOOG 2004-01/Young Boost SRCTN45066831Microarray analysis in breast cancer to Tailor Adjuvant Drugs Or Regimens, a randomized phase III study. MATADOR, BOOG 2005-02, CKTO 2004-04 ISRCTN61893718A prospective randomised, open, multicentre, phase III study to assess different Durations of Anastrozole therapy after 2–3 years Tamoxifen as Adjuvant therapy in postmenopausal women with breast cancer. 2006-01/DATAA randomized, open-label phase III study of first line chemotherapy in elderly metastatic breast cancer patients, comparing intravenous pegylated liposomal doxorubicin with oral capecitabine; and the incorporation of a complete geriatric assessment. 2006-02/OMEGABOOG participation in International studies:. BOOG 2001-01/TEAM trial. BOOG 2001-02/AMAROS (EORTC 10981/22023). BOOG 2002-04/HERA (BIG 1-01/EORTC 10011/BO16348B). BOOG 2003-02 (BIG 1-02/IBCSG 27-02). BOOG 2003-04 (GBG 29). BOOG 2004-02/TBP (GBG 26, BIG 3-05). BOOG 2005-01/CASA (IBCSG 32-05/BIG 1-05). BOOG 2005-03/MINDACT (EORTC 10041, BIG 3-04). BOOG 2006-03/SUPREMO (BIG 2-04). BOOG 2006-04/Adjuvant lapatinib study (BIG 2-06/EGF106708)

Download Full-text

Association of Breast Surgeons at the British Association of Surgical Oncology (ABS AT BASO)

Breast Cancer Online ◽

10.1017/s1470903106009011 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 28-33

Author(s):

Keyword(s):

Clinical Trials ◽

Ductal Carcinoma ◽

Randomised Trial ◽

Surgical Oncology ◽

British Association ◽

List Type ◽

Current Contact ◽

Trial Testing ◽

Er Positive

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Association of Breast Surgeons at the British Association of Surgical Oncology (ABS at BASO). Clinical trials include: BASO DCIS II TRIAL: Randomised trial testing observation (no radiotherapy) against radiotherapy in women with low-risk completely excised ER positive ductal carcinoma in situ (DCIS) of the breast on adjuvant endocrine therapy.Neoadjuvant trial of preoperative exemestane or letrozole ± celecoxib in the treatment of ER positive postmenopausal early breast cancer.

Download Full-text